← The Wire
YDESNasdaq
YD Bio Ltd
Services-Medical Laboratories · E9 · CIK 2011674
The provided text does not contain a business description for YD Bio Ltd
$163M
Market cap
$2.30
Last close
+6.0%
1D
+0.4%
5D
143K
Volume
Price$2.30-81.6%· 1Y
Volume
Aug 29L $1.90 · H $23.11Aug 3
Revenue & earnings
RevenueNet incomeLoss
Fundamentals & quality
Trailing fundamentals · via Polygon & SECRev growth YoY
16.9%
Trailing 12 months
Gross margin
—
Gross profit / revenue
Net margin
—
Net income / revenue
ROE
—
Return on equity
ROIC
-34.3%
Return on invested capital
FCF yield
-4.9%
Free cash flow / mkt cap
P/E
—
Price / earnings
P/S
—
Price / sales
EV/EBITDA
—
Valuation multiple
Debt / equity
—
Leverage
Piotroski F
1/9
Fundamental strength
Altman Z
3.29Safe
Distress model
Similar companies
Comparable business profile · signals at a glance
Filings archive
Newest first · each with a one-line AI read · showing 10 of 17May 1, 20266-KREPORT OF FOREIGN PRIVATE ISSUERYD Bio Limited announced its financial results for the year ended December 31, 2025, via a press release issued on April 30, 2026. The press release is furnished as Exhibit 99.1 to this Report on Form 6-K.Apr 30, 202620-FANNUAL REPORTYD Bio Limited reported a net loss of $8,311,316 for the fiscal year ended December 31, 2025, an increase from a net loss of $1,411,559 in 2024. The company's management has identified substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flows.Feb 26, 20266-KREPORT OF FOREIGN PRIVATE ISSUERYD Bio Limited announced a strategic partnership between its subsidiary, YD Bio USA, Inc., and YC Biotech Co., Ltd. to create a "Taiwan-U.S. Dual-Core" regulatory platform for U.S. Food and Drug Administration (FDA) submissions. This partnership will involve YD Bio USA serving as YC Biotech's exclusive U.S. Agent and liaison with the FDA for its Asian Contract Research Organization clients.Jan 30, 20266-KREPORT OF FOREIGN PRIVATE ISSUERYD Bio Limited entered into a binding letter of intent to acquire Safe Save Medical Cell Sciences & Technology Co., Ltd. for an expected total consideration of NT$839,832,000. The transaction is subject to customary closing conditions and due diligence, with a target closing within 30 days after March 20, 2026.Jan 21, 20266-KREPORT OF FOREIGN PRIVATE ISSUERYD Bio Limited announced the appointment of new directors to its Board committees and that it has regained compliance with Nasdaq's Audit Committee requirements.Jan 16, 20266-KREPORT OF FOREIGN PRIVATE ISSUERYD Bio Limited announced changes to its Board of Directors, with four directors removed and two new directors elected, effective December 30, 2025. This action was taken via a shareholders' written consent from majority stockholders YD Biopharma Holding Limited and EG Biomed Limited.Jan 15, 20266-KREPORT OF FOREIGN PRIVATE ISSUERYD Bio Limited made available an investor presentation on January 15, 2026, for use at investor conferences and meetings. This presentation is furnished as an exhibit to this report.Jan 6, 20266-KREPORT OF FOREIGN PRIVATE ISSUERYD Bio Limited changed its independent registered public accounting firm, dismissing ARK Pro CPA & Co and appointing Malone Bailey, LLP. This change was effective immediately on December 24, 2025.Nov 17, 20256-KREPORT OF FOREIGN PRIVATE ISSUERYD Bio Limited announced the resignation of its Audit Committee Chair and the appointment of a new Audit Committee Chair. The company also received notification that Ms. Jan Hall no longer qualifies as an independent director.Sep 30, 20256-KREPORT OF FOREIGN PRIVATE ISSUERYD Bio Limited filed a Form 6-K on September 30, 2025, containing unaudited interim financial statements for YD Bio Limited, YD Biopharma Limited, and Breeze Holdings Acquisition Corp., along with related management discussions and analysis. The filing also includes unaudited pro forma condensed combined and consolidated financial information and a press release dated September 30, 2025.
Show 7 more ↓
Sep 26, 20256-KREPORT OF FOREIGN PRIVATE ISSUERYD Bio Limited announced the resignation of its Chief Operating Officer, Ms. May Tsai, for personal health reasons, and the engagement of Ms. Nina Wu as a strategic consultant to assist with investor communications and capital markets interaction. The Company also filed a registration statement to register ordinary shares underlying its public warrants, which will not be exercisable until the statement is amended and declared effective.Sep 19, 20256-KREPORT OF FOREIGN PRIVATE ISSUERYD Bio Limited has changed its independent registered public accounting firm, terminating its engagement with CBIZ CPAs P.C. and engaging ARK Pro CPA & Co. for the fiscal year ending December 31, 2025.Aug 15, 20256-KREPORT OF FOREIGN PRIVATE ISSUERYD Bio Limited has secured $13.2 million in PIPE financing commitments, with Ms. Hsiao Lan Wu replacing Dr. Keng-Lian Ou as a subscriber on the same terms. This substitution occurred on August 13, 2025, and the total financing commitment remains unchanged.Jun 21, 2024425FORM 425Mar 21, 2024425FORM 425Mar 15, 2024425FORM 425Feb 14, 2024S-4REGISTRATION STATEMENT